Megan S Farris1, Glenda MacQueen1, Benjamin I Goldstein2,3, JianLi Wang4,5, Sidney H Kennedy6,7,8,9,10, Signe Bray1,11,12,13, Catherine Lebel1,11,12,13, Jean Addington1. 1. 1 Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 2. 2 Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 3. 3 Departments of Psychiatry and Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. 4 Work & Mental health Research Unit, Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada. 5. 5 Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. 6. 6 Department of Psychiatry, University Health Network, Toronto, Ontario, Canada. 7. 7 Department of Psychiatry, St. Michael's Hospital, Toronto, Ontario, Canada. 8. 8 Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, St. Michael's Hospital, Toronto, Ontario, Canada. 9. 9 Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada. 10. 10 Krembil Research Institute, University Health Network, Toronto, Ontario, Canada. 11. 11 Department of Radiology, University of Calgary, Calgary, Alberta Canada. 12. 12 Alberta Children's Hospital Research Institute, Calgary, Alberta Canada. 13. 13 Child & Adolescent Imaging Research (CAIR) Program, Calgary, Alberta, Canada.
Abstract
OBJECTIVE: The aim was to describe treatment history including medications, psychosocial therapy and hospital visits of participants in the Canadian Psychiatric Risk and Outcomes Study (PROCAN). METHODS: PROCAN is a 2-site study of 243 youth/young adults aged 12 to 25 y, categorized into 4 groups: healthy controls ( n = 42), stage 0 (non-help seeking, asymptomatic with risk mainly family history of serious mental illness (SMI); n = 41), stage 1a (distress disorders; n = 52) and stage 1b (attenuated syndromes; n = 108). Participants were interviewed regarding lifetime and current treatments, including medications, psychosocial therapies and hospital visits. RESULTS: The number receiving baseline medications differed significantly across groups ( P < 0.001): 0% healthy controls, 14.6% stage 0, 32.7% stage 1a and 34.3% stage 1b. Further, 26.9% and 49.1% of stage 1a and stage 1b participants received psychosocial therapy at baseline, indicative of statistically significant differences among the groups ( P < 0.001). Similar results were observed for lifetime treatment history; stage 1b participants had the highest frequency of lifetime treatment. Medications started in adulthood (>18 y of age) were the most common for initiation of treatment compared to childhood (0 to 12 y) and adolescence (13 to 17 y) for stage 1a and 1b participants. Lifetime mental health hospital visits differed significantly across groups ( P < 0.001) and were most common in stage 1b participants (29.6%) followed by stage 1a (13.5%), stage 0 (4.9%) and healthy controls (2.4%). CONCLUSION: We found that treatment history for participants in the PROCAN study differed among the at-risk groups. Future initiatives focused on determining the effects of treatment history on SMI are warranted.
OBJECTIVE: The aim was to describe treatment history including medications, psychosocial therapy and hospital visits of participants in the Canadian Psychiatric Risk and Outcomes Study (PROCAN). METHODS: PROCAN is a 2-site study of 243 youth/young adults aged 12 to 25 y, categorized into 4 groups: healthy controls ( n = 42), stage 0 (non-help seeking, asymptomatic with risk mainly family history of serious mental illness (SMI); n = 41), stage 1a (distress disorders; n = 52) and stage 1b (attenuated syndromes; n = 108). Participants were interviewed regarding lifetime and current treatments, including medications, psychosocial therapies and hospital visits. RESULTS: The number receiving baseline medications differed significantly across groups ( P < 0.001): 0% healthy controls, 14.6% stage 0, 32.7% stage 1a and 34.3% stage 1b. Further, 26.9% and 49.1% of stage 1a and stage 1b participants received psychosocial therapy at baseline, indicative of statistically significant differences among the groups ( P < 0.001). Similar results were observed for lifetime treatment history; stage 1b participants had the highest frequency of lifetime treatment. Medications started in adulthood (>18 y of age) were the most common for initiation of treatment compared to childhood (0 to 12 y) and adolescence (13 to 17 y) for stage 1a and 1b participants. Lifetime mental health hospital visits differed significantly across groups ( P < 0.001) and were most common in stage 1b participants (29.6%) followed by stage 1a (13.5%), stage 0 (4.9%) and healthy controls (2.4%). CONCLUSION: We found that treatment history for participants in the PROCAN study differed among the at-risk groups. Future initiatives focused on determining the effects of treatment history on SMI are warranted.
Authors: Cynthia A Beck; Jeanne V A Williams; Jian Li Wang; Aliya Kassam; Nady El-Guebaly; Shawn R Currie; Colleen J Maxwell; Scott B Patten Journal: Can J Psychiatry Date: 2005-09 Impact factor: 4.356
Authors: Rosemary Purcell; Anthony F Jorm; Ian B Hickie; Alison R Yung; Christos Pantelis; G Paul Amminger; Nick Glozier; Eoin Killackey; Lisa J Phillips; Stephen J Wood; Susy Harrigan; Andrew Mackinnon; Elizabeth Scott; Daniel F Hermens; Adam J Guastella; Amanda Kenyon; Laura Mundy; Alissa Nichles; Antoinette Scaffidi; Daniela Spiliotacopoulos; Lara Taylor; Janet P Y Tong; Suzanne Wiltink; Natalia Zmicerevska; Patrick D McGorry Journal: Early Interv Psychiatry Date: 2014-03-28 Impact factor: 2.732
Authors: Kristin S Cadenhead; Jean Addington; Tyrone Cannon; Barbara Cornblatt; Thomas McGlashan; Diana Perkins; Larry Seidman; Ming Tsuang; Elaine Walker; Scott Woods; Robert Heinssen Journal: Early Interv Psychiatry Date: 2010-08 Impact factor: 2.732
Authors: Ronald C Kessler; G Paul Amminger; Sergio Aguilar-Gaxiola; Jordi Alonso; Sing Lee; T Bedirhan Ustün Journal: Curr Opin Psychiatry Date: 2007-07 Impact factor: 4.741